Guangzhou Xiangxue Pharmaceutical Co. Ltd.

3 articles about Guangzhou Xiangxue Pharmaceutical Co. Ltd.

• Athenex Expands its Strategic Partnership with Guangzhou Xiangxue Pharmaceutical Through a Licensing Agreement for its Product Candidates Oral Paclitaxel and Oral Irinotecan, as well as Tirbanibulin Ointment, in China, Hong Kong and Macao

  12/16/2019

  The agreement covers China, Hong Kong and Macao (the “Territory”) and represents an expansion of the existing relationship between the two companies.

• 

  Athenex Scores $100 Million in Financing, Kicks off Joint Venture in China for Development of TCR...

  7/2/2018

  Athenex is kicking off the second half of 2018 with a bang. The company secured $100 million in investments from Perceptive Advisors, is making major inroads in China with a joint venture with Chinese biotech Xiangxue Life Sciences and an in-licensing agreement from Avalon PolyTom Limited.

• Athenex And Its Partner, Guangzhou Xiangxue Pharma, Announced Chinese FDA IND Approval To Begin Clinical Trials Of KX-02 Tablet For Glioblastoma

  5/25/2017